Patents by Inventor Kevin Wayne Kuntz

Kevin Wayne Kuntz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20210137936
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 25, 2020
    Publication date: May 13, 2021
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20210130342
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20210060027
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: July 9, 2020
    Publication date: March 4, 2021
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20210053948
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 5, 2020
    Publication date: February 25, 2021
    Inventors: Heike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20210032251
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20210024502
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: August 11, 2020
    Publication date: January 28, 2021
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION
    Publication number: 20210017163
    Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Inventors: Kevin Wayne KUNTZ, Hyeong Wook CHOI, Steven MATHIEU, Kristen SANDERS, Arani CHANDA
  • Pyridazinones as PARP7 inhibitors
    Patent number: 10870641
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 22, 2020
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 10821113
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 3, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Combination therapy for treating cancer
    Patent number: 10787440
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 29, 2020
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Kevin Wayne Kuntz
  • QUINAZOLINONES AS PARP14 INHIBITORS
    Publication number: 20200247788
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: January 6, 2020
    Publication date: August 6, 2020
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Hydrochloride salt form for EZH2 inhibition
    Patent number: 10710987
    Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: July 14, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Hyeong Wook Choi, Steven Mathieu, Kristen Sanders, Arani Chanda
  • Isoxazole carboxamides as irreversible SMYD inhibitors
    Patent number: 10669243
    Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: June 2, 2020
    Assignee: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • ISOXAZOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20200148650
    Abstract: The present disclosure provides substituted isoxazole carboxamide compounds having Formula (1) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2 Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 30, 2019
    Publication date: May 14, 2020
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • Substituted Cyclohexylamine Compounds
    Publication number: 20200123142
    Abstract: The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 23, 2020
    Applicant: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20200123134
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 23, 2020
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • SUBSTITUTED PYRROLIDINE COMPOUNDS
    Publication number: 20200102314
    Abstract: The present disclosure provides substituted pyrrolidine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: August 5, 2019
    Publication date: April 2, 2020
    Applicant: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
  • Substituted piperidine compounds
    Patent number: 10577363
    Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 3, 2020
    Assignee: EPIZYME, INC.
    Inventors: Lorna Helen Mitchell, Andrew Simon Bell, Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Michael John Munchhof
  • Quinazolinones as PARP14 inhibitors
    Patent number: 10562891
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 18, 2020
    Assignee: Ribon Therapeutics Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS
    Publication number: 20200048195
    Abstract: The present disclosure provides pyrrolidine carboxamide compounds having Formula I and the pharmaceutically acceptable salts and solvates thereof, wherein A, B, X, Y, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: May 28, 2019
    Publication date: February 13, 2020
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY